Novo Nordisk expands research collaboration to develop hemophilia drug
![Photo: Stine Tidsvilde](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13547187.ece/ALTERNATES/schema-16_9/doc7irz9n2kbz413aiji9go.jpg)
Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.